Product Overview

AOP Orphan's focus is on Rare Diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to Rare Diseases.

Neurology & Metabolic Disorders

Adasuve®

Adasuve® is indicated for the rapid control of mild-to-moderate agitation (increased, unproductive physical activity coupled with internal tension) in adult patients with schizophrenia or biopolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms. 

Drug Facts
Active Ingredient
Loxapine
HematoOncology

Anagrelide AOP

Anagrelide AOP

Drug Facts
Active Ingredient
Anagrelide
HematoOncology

BESREMi®

BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.

Drug Facts
Active Ingredient
Ropeginterferon alfa-2b
Neurology & Metabolic Disorders

Feraccru®

Feraccru® is indicated for adults for the treatment of iron deficiency.

Drug Facts
Active Ingredient
Ferric-maltol
Neurology & Metabolic Disorders

Ocaliva®

Ocaliva® is indicated for the treatment of primary biliary cholangitis (also known to as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.

Drug Facts
Active Ingredient
Obeticholic acid
Neurology & Metabolic Disorders

Wakix®

Wakix® is indicated in adults for the treatment of narcolepsy with or without cataplexy.

Drug Facts
Active Ingredient
Pitolisant